Longeveron vs Prokidney
Longeveron is the larger business, with $1.2m of revenue in fiscal 2025 against $893,000 for Prokidney (1.3 times as much). Prokidney grew faster (1075.0% against -49.9%). Longeveron kept more of each dollar of sales as profit: a net margin of -1893.6% against -7725.2%.
| Latest fiscal year | LongeveronLGVN, 2025 | ProkidneyPROK, 2025 |
|---|---|---|
| Revenue | $1.2m | $893,000 |
| Revenue growth | -49.9% | 1075.0% |
| Net income | −$22.7m | −$69.0m |
| Operating margin | -1942.2% | -18477.8% |
| Net margin | -1893.6% | -7725.2% |
| Return on equity | -164.7% | — |
| Free cash flow | −$18.9m | −$135m |
| Cash | $4.7m | $109m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $0 |
| Employees | 37 | 231 |
| Market value | $53.7m | $234m |
| Price vs our value range | — | — |
| Moat score | 19 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 10 sales |